Title:
MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/038096
Kind Code:
A1
Abstract:
A monoclonal antibody or an antigen-binding fragment thereof is a monoclonal antibody against an influenza virus A hemagglutinin antigen or an antigen-binding fragment of the monoclonal antibody, wherein the monoclonal antibody or the antigen-binding fragment can bind to influenza virus A and has an activity to inhibit the proliferation of the virus. The monoclonal antibody or the antigen-binding fragment has at least one domain selected from the group consisting of a light-chain variable domain containing (a) to (c) and a heavy-chain variable domain containing (d) to (f). A pharmaceutical composition is one for treating or preventing an influenza virus A disease in a subject and contains the monoclonal antibody or an antigen-binding fragment thereof as an active ingredient. A gene is one containing any one of DNA molecules (g) to (j) and any one of DNA molecules (k) to (n) and comprises DNA encoding a protein capable of binding to influenza virus A and having an activity to inhibit the proliferation of the virus. An expression vector contains the gene.
Inventors:
KAWAOKA YOSHIHIRO (JP)
YAMAYOSHI SEIYA (JP)
ITO MUTSUMI (JP)
URAKI RYUTA (JP)
YAMAYOSHI SEIYA (JP)
ITO MUTSUMI (JP)
URAKI RYUTA (JP)
Application Number:
PCT/JP2017/029911
Publication Date:
March 01, 2018
Filing Date:
August 22, 2017
Export Citation:
Assignee:
UNIV TOKYO (JP)
International Classes:
C07K16/10; C12N15/09
Foreign References:
| JP2016516090A | 2016-06-02 | |||
| JP2014527403A | 2014-10-16 | |||
| US20140370032A1 | 2014-12-18 | |||
| JP2014523254A | 2014-09-11 |
Other References:
CHO, A. ET AL.: "Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine", CURRENT OPINION IN VIROLOGY, vol. 17, March 2016 (2016-03-01), pages 110 - 115, XP055604030
Attorney, Agent or Firm:
TANAI Sumio et al. (JP)
Download PDF: